Announced Thu, 21 May · 13:27 IST

Audited Results for fiancial yaer ended 31.03.2026

Revenue DeclinePat NegativeNegative Operating CashflowDebt Equity ThresholdResults View source PDF

KREBSBIO · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reaction · full curve 14 horizons · vs prior close
+4.4%1-day move
₹56.38
prior close
₹55.30
base price
In-mkt
timing
5m10m15m30m1D2D3D4D5D7D15D1M2M3M
+0.0+0.0+0.0+1.2+4.4+9.6+15.1+20.9+16.4+15.3+17.0+14.6-1.7
Up moveDown movePending
AI summary

Krebs Biochemicals reported revenue of Rs 2,373.16 Lacs for FY2026, down sharply from Rs 4,331.19 Lacs in FY2025 – a revenue decline of approximately 45% year-on-year. The company posted a loss before tax of Rs 1,693.31 Lacs, which is an improvement from the Rs 2,692.40 Lacs loss in the previous year. The net worth stands deeply negative at Rs 16,275.47 Lacs due to accumulated losses. The Vizag manufacturing unit has remained closed since February 7, 2025 following an Andhra Pradesh Pollution Control Board order, severely impacting operations. Cash flow from operations was negative at Rs 192.05 Lacs. Statutory auditors Bhavani & Co issued an unmodified (clean) audit opinion on the financial statements.

Likely market impact

The company continues to burn cash with no manufacturing operations and deeply negative net worth, raising serious questions about its ability to remain a going concern despite the clean audit. The clean audit opinion is notable given the severe financial distress. Shareholders face extreme risk as equity has been completely eroded.